Regulus Therapeutics (RGLS) Misses Q3 EPS by 2c

Regulus Therapeutics (NASDAQ: RGLS) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16).

As of September 30, 2017, Regulus had cash, cash equivalents and short-term investments of $71.4 million.

For earnings history and earnings-related data on Regulus Therapeutics (RGLS) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Kepler Cheuvreux Downgrades Volkswagen AG (VOW:GR) (VWAGY) to Hold
• Canaccord Starts L1 Group Ltd (L1G:AU) at Buy